Thermo Fisher Scientific Inc (NYSE: TMO) Q1 2023 earnings call dated Apr. 26, 2023
Corporate Participants:
Rafael Tejada — Vice President Investor Relations
Marc N. Casper — Chairman, President and Chief Executive Officer
Stephen Williamson — Senior Vice President and Chief Financial Officer
Analysts:
Jack Meehan — Nephron Research — Analyst
Rachel Vatnsdal — JPMorgan — Analyst
Derik de Bruin — Bank of America — Analyst
Dan Brennan — Cowen — Analyst
Matthew Sykes — Goldman Sachs — Analyst
Vijay Kumar — Evercore — Analyst
Dan Arias — Stifel — Analyst
Puneet Souda — SVB — Analyst
Presentation:
Operator
Good morning, ladies and gentlemen and welcome to the Thermo Fisher Scientific 2023 First Quarter Conference Call. My name is Charlie and I’ll be coordinating the call today. [Operator Instructions] I would like to introduce our moderator for today’s call Mr. Rafael Tejada, Vice President of Investor Relations.
Mr. Tejada, you may begin the call.
Rafael Tejada — Vice President Investor Relations
Good morning and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President and Chief Executive Officer and Stephen Williamson, Senior Vice-President and Chief Financial Officer. Please note this call is being webcast live and will be archived on the Investors section of our website, thermofisher.com under the heading News & Events until May 12, 2023. A copy of the press release of our first-quarter 2023 earnings is available in the Investors section of our website under the heading Financials. So before we begin, let me briefly cover our safe harbor statement.
Various remarks that we may make about the company’s future expectations, plans and prospects, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K, which is on file with the SEC and available in the Investors section of our website under the heading Financials SEC filings. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Therefore you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. Also during this call, we will be referring to certain financial measures, not prepared in accordance with generally accepted accounting principles or GAAP.
A reconciliation of these non-GAAP financial measures to the most directly-comparable GAAP measures is available in the press release of our first-quarter 2023 earnings and also available in the Investors section of our website under the heading Financials.
So with that, I’ll now turn the call over to Marc.
Marc N. Casper — Chairman, President and Chief Executive Officer
Thank you Raf. Good morning everyone and thanks for joining us today for our first-quarter call. As you saw in our press release, we had a very strong start to the year. We delivered another quarter of very strong financial performance. Our core business is performing very well. I am pleased with the team’s great execution and the share gain we saw across our company, especially within the context of a slightly more challenging macro-environment. Our continued success is the result of our proven growth strategy, the trusted partner status that we’ve earned with our customers and our PPI business system, which is a differentiator for us and enables operational excellence within the company.
So, let me first recap the financials, our revenue in the quarter was $10.71 billion. Our adjusted operating income was $2.33 billion and we delivered another quarter of strong adjusted EPS performance achieving $5.03 per share. At the beginning of the year, we set-out appropriately ambitious guidance for 2023 and Q1 demonstrates that we’re delivering against that. Let me turn to our end-markets. We delivered very strong performance in Q1 driven by outstanding execution from our team, resulting in meaningful share gain. Pandemic related activity performed as we had expected during the quarter.
As a reminder, the impact of the headwind from the revenue run off can be seen in pharma and biotech due to vaccines and therapies and in diagnostics and healthcare due to COVID-19 testing. Let me give you some color on our end-markets. Starting with pharma and biotech, we delivered growth in the mid single-digits for the quarter. During the quarter, we had very strong performance in our pharma services, clinical research and chromatography and mass spectrometry businesses. In academic and government, we grew in the high-single-digits in the quarter, we delivered strong growth across a range of our businesses, including chromatography and mass-spectrometry, electron microscopy, as well as the research and safety market channel.
Academic and government demand were strong in all regions. In industrial and applied, we grew in the high-single-digits for the quarter, we saw strong growth in all of our analytical instrument businesses including electron microscopy, chemical analysis and chromatography and mass-spectrometry. Finally, in diagnostics and healthcare in Q1, revenue was approximately 45% lower than the prior year quarter. The team delivered very good core business growth during the quarter, led by our immunodiagnostics, microbiology and transplant diagnostic businesses.
I’ll now turn to our proven growth strategy, which enables us to continue to deliver differentiated performance and setting us up for an even brighter future.
As a reminder, our growth strategy consists of three pillars. Developing high-impact, innovative new products, leveraging our scale in the high-growth and emerging markets and delivering a unique value proposition to our customers. Starting with the first pillar innovation, we had an excellent start to the year as we launched a number of high-impact new products across our businesses during the first-quarter. These technologies are further strengthening our industry leadership by enabling our customers to break new ground in their important work.
In elemental analysis, we launched the Thermo Scientific iCAP RQ Plus ICP-MS analyzer. This ICP mass-spectrometry system simplifies analysis of trace elements in complicated samples, including the identification of heavy metals in soil and water as well as toxic elements in food and beverage. In genetic sciences, we launched the Applied Biosystems QuantStudio Absolute Q AutoRun dPCR suite, an automated digital PCR solution to increase productivity for molecular research, including cell and gene therapy and cancer research.
In our Biosciences business, we launched the Invitrogen DynaGreen microplastic-free magnetic beads for protein purification. This new product will help our customers to reduce the environmental impact of life science research and builds on our long history of innovation and market leadership in bioscience reagents. And in our clinical diagnostics business, we launched the Thermo Scientific DRI tramadol assay, which broadens our extensive toxicology portfolio with a new drug of abuse assay to help fight the opioid crisis. These are just a few examples of the innovation going on across our company and I’m excited about the robust pipeline of products that will be launched throughout the year.
We also recently learned that Thermo Fisher was ranked number 22 on Fortune’s Most Innovative Companies list. This is a new award launched in 2023, based on product and process innovation and the company’s culture, a really nice recognition of our team and their track-record. The second pillar of our growth strategy is leveraging our scale in the high-growth and emerging markets to create a differentiated experience for our customers. We continue to strengthen our capabilities serving these markets by opening a new Gibco cell culture rapid prototyping facility at our existing site in Suzhou, China.
This facility will help regional customers accelerate the transition of their cell culture media production into current good manufacturing practices, it will also ensure patients receive therapies manufactured at the highest-level of safety, effectiveness, quality and purity. Turning to the third pillar of our growth strategy, we continue to enhance our customer value proposition by strengthening our capabilities to enable our customers to make the world healthier, cleaner and safer. I’ve had the opportunity to meet with dozens of our pharmaceutical and biotech customers since the beginning of the year and our value proposition is clearly resonating.
Our trusted partner status gives us an early understanding of customers’ unmet needs and the ability to generate insights that allow for deep collaborations that continue to advance scientific breakthroughs. During Q1, we achieved an exciting milestone in our strategic partnership with the University of California, San Francisco with the opening of a new cell therapy cGMP manufacturing and collaboration center to accelerate the development of breakthrough therapies for glioblastoma, multiple myeloma and other cancers.
In this facility, we offer UCSF and other customers solutions for cell therapy development from discovery to clinical research through to commercial manufacturing. Partnerships like this have the potential to transform clinical care. Another example of our customer value proposition and the trusted partner status that we have established with our pharma and biotech customers can be seen in the excellent performance of our clinical research business, which drove very strong growth in the quarter. I’m very excited by the revenue synergies that will drive both short-term and longer-term growth in the business, the momentum is continuing to build and is benefiting both our clinical research business and other parts of the company.
We’re also working with very engaged customers on longer-term projects to explore ways to reduce the time and cost of bringing drugs to market. By bringing our capabilities and expertise within our pharma services and clinical research businesses together, we are working to improve the effectiveness of the drug development process, benefiting both our customers and their patients. We have an exciting pilot underway that is utilizing dedicated resources and best-in class technologies and capabilities to provide enhanced visibility and real-time data to the customer. This improves the speed of decision-making and reduces potential delays from development to manufacturing to clinical trials.
It can also help our customers take cost-out of the process by reducing waste in the clinical supply process. This is really a nice example of why we are the trusted partner. As always, our PPI Business System and our mission-driven culture enabled our success during the quarter. PPI engages and empowers all of our colleagues to find a better way, every day and it enables us to improve quality, productivity and the customer experience, while also helping us to navigate a dynamic environment.
You can see the positive impact of our PPI business system in our results in Q1. It has also allowed us to capitalize on the strong demand from customers for analytical instrumentation and has also helped us to effectively address the runoff in pandemic related activity and appropriately manage our costs. Moving to capital deployment, we’ve had an active start to the year, both in strategic M&A and return capital to our shareholders. We closed the acquisition of the Binding Site at the beginning of the year. It’s great to have this business now as part of the company. The business is a fantastic fit with our specialty diagnostics business and we’re leveraging our capabilities to take an excellent business and make it even better. The integration is going very smoothly and the business is performing very well, tracking ahead of plan.
Our team is focused on advancing the diagnosis and management of patients with multiple myeloma and immune disorders and the innovation pipeline looks great. We’re excited by the opportunity to further advance patient-care in this area. In terms of return of capital during the quarter, we repurchased $3 billion of stock and increased our dividend by 17%, so overall, a great start to the year from capital deployment. During the quarter, we also advanced our environmental, social and governance priorities, including securing agreements to power all current US sites with 100% renewable energy by 2026.
This is a significant contribution to our 2030 commitment to a 50% reduction in Scope I and II greenhouse gas emissions. As we continue to transition away from fossil fuels and adopt renewable energy, we’re also accelerating our progress towards our commitment to net zero carbon emissions by 2050. We’ll be releasing our latest Corporate Social Responsibility Report later this quarter and we’ll give our stakeholders a really substantive review on our continuous improvement and the positive impact that we’re happening.
Let me now turn to our guidance. Since the beginning of the year, the macro-environment has become slightly more challenging. We’re stepping up to that challenge and our proven growth strategy powered by our PPI Business System is enabling us to maintain our ambitious full-year outlook, with revenues of $45.3 billion and adjusted EPS of $23.70. Stephen will take you through the details in his remarks. So, to summarize our key takeaways from the first-quarter.
Our very strong results in Q1 were driven by our proven growth strategy and PPI business system. Our business is performing very well. Our unique customer value proposition is further elevating our trusted partner status and we’re continuing to gain market-share. We effectively deploy capital to create significant value for our customers and shareholders and we’re incredibly well-positioned to deliver differentiated performance and an excellent 2023 as we continue to create value for all of our stakeholders and build an even brighter future for our company.
With that, I’ll now hand the call over to our CFO, Stephen Williamson. Stephen?
Stephen Williamson — Senior Vice President and Chief Financial Officer
Thanks Marc and good morning everyone. As you saw in our press release, we started the year with a very strong Q1. Our growth strategy powered by our PPI Business System is enabling us to continue to very effectively navigate the company through a dynamic macro-environment, manage the runoff in pandemic related revenue and drive excellent core organic revenue growth and share gains. In the quarter, we delivered $10.7 billion of revenue, which included 6% core organic revenue growth and we delivered $5.03 of adjusted EPS. Our core organic revenue growth was 1% higher than we’d incorporated in our previous 2023 guidance and adjusted EPS was $0.02 ahead.
So, very strong start to the year. Let me now provide you with some more details on our performance. So beginning with our earnings results, as I mentioned, we delivered $5.03 of adjusted EPS in Q1. GAAP EPS in the quarter was $3.32. On the topline, reported revenue was 9% lower year-over-year. The components of our Q1 reported revenue included 8% lower organic revenue, a 1% contribution from acquisitions and a headwind of 2% from foreign-exchange. Pandemic related revenue came in as we expected in Q1, this is comprised of $140 million in testing revenue and $180 million of vaccines and therapies revenue.
As I had mentioned earlier, core organic revenue growth in the quarter was 6% and as a reminder, core organic revenue growth continues to include the change in our COVID-19 vaccines and therapies revenue, which was a headwind of approximately 3% in the quarter so very strong core performance showing the continued strength of our business. Turning to our organic revenue performance by geography. The organic growth rates by region are skewed by the pandemic related revenue in the current and prior year. In Q1, North America declined high-single digits, Europe declined in the low-double-digits, Asia-Pacific grew in the low-single digits with China declining slightly and rest-of-world declined high-single-digits.
With respect to our operational performance adjusted operating income in the quarter decreased 32% and adjusted operating margin was 21.8%, 740 basis-points lower than Q1 last year. In the quarter, we achieved strong price realization to effectively address inflation while also driving strong productivity, this was more than offset by lower pandemic related revenue and continued strategic investments. Total company adjusted gross margin in the quarter came in at 40.3%, 720 basis-points lower than Q1 last year.
For the first-quarter, the change in gross margin was due to the same drivers as those for our adjusted operating margin. Moving on to the details of the P&L, adjusted SG&A in the quarter was 15.3% of our revenues. Total R&D expenses, $350 million in Q1, reflecting our ongoing investments in high-impact innovation. R&D as a percent of manufacturing revenue was 6.9% in the quarter. Looking at our results below-the-line for the quarter, our net interest expense was $154 million which is $36 million higher than Q1 last year, mainly due to capital deployment. Our adjusted tax-rate in the quarter was 10%, this is 410 basis-points lower than Q1 last year, reflecting the results of our tax planning activities.
Average diluted shares were 388 million in Q1, approximately 6 million lower year-over-year, driven by share repurchases, net of option dilution. Turning to cash-flow on the balance sheet, cash-flow from operations was $730 million. Free-cash flow for Q1 was $280 million after investing $450 million in net capital expenditures. During the quarter, we deployed $5.8 billion of capital, this included $2.7 billion for the acquisition of the Binding Site and $3.1 billion of capital returned to shareholders through buybacks and dividends.
We ended the quarter with $3.5 billion in cash and $35.3 billion of total debt. Our leverage ratio at the end-of-the quarter was 3.2 times gross debt to adjusted EBITDA and 2.9 times on a net-debt basis. Concluding my comments on our total company performance suggested ROIC was 12.2%, reflecting the strong returns on investments that we’re generating across the company. Now, provide some color on the performance of our four business segments. Let me start with a couple of framing comments.
The scale and margin profile of our pandemic related revenue varies by segments, net revenue was significantly higher in the prior year so that does skew some of the reported segment growth rates and margins. We continue to execute strong pricing realization across all segments to address higher inflation. Moving on to the segment details, starting with Life Science Solutions, Q1 reported revenue in this segment declined 38% and organic revenue was 37% lower than the prior year quarter. This was driven by the moderation in pandemic related revenue in the segment versus the year-ago quarter. Q1 adjusted operating income in-life science solutions decreased 62% and adjusted operating margin was 32%, down 19 percentage points versus the prior year quarter.
In the quarter, we delivered good productivity, which was more than offset by unfavorable volume mix due to the significantly higher pandemic related revenue in Q1, 2022. In the Analytical Instruments segment reported revenue increased 14% in Q1 and organic growth was 17%. The strong growth was broad-based in the segment this quarter, led by chromatography and mass spectrometry and the electron microscopy businesses. Q1 adjusted operating income in the segment increased 40% and adjusted operating margin was 24.4% up 460 basis-points year-over-year.
In the quarter, we delivered strong volume pull-through, strong productivity and favorable business mix. This was partially offset by strategic investments. Turning to Specialty Diagnostics, in Q1 reported revenue declined 25% and organic revenue was 28% lower than the prior year quarter. In Q1, we continued to see strong underlying growth in the core, led by our immunodiagnostics microbiology and transplant diagnostics businesses. This was offset by lower pandemic related revenue versus the year-ago quarter.
Q1 adjusted operating income decreased 21% in the quarter and adjusted operating margin was 25.3%, which is 140 basis-points higher than Q1, 2022. During the quarter, we delivered favorable business mix and strong productivity, which was partially offset by the impact of lower COVID-19 testing volume. Finally in laboratory products and biopharma services segment Q1 reported revenue increased 6% and organic growth was 7%. During Q1, organic revenue growth in this segment was led by the pharma services and clinical research businesses. Q1 adjusted operating income in the segment increased 28% and adjusted operating margin was 13.8% which is 240 basis-points higher than Q1 2022. In the quarter, we delivered strong productivity and volume pull-through which was partially offset by strategic investments. So, let me now turn to guidance. And as Marc outlined, we’re maintaining our guidance for the full-year 2023, consisting of revenue guidance of $45.3 billion including 7% core organic revenue growth and adjusted EPS guidance of $23.70.
There is no net change overall in our guidance, but how we expect to achieve this guidance is different from the way we planned at the start of the year and it demonstrates our ability to effectively navigate the dynamic macro environment and maintain a very strong financial outlook. Since our initial guide we see $0.25 of additional headwinds to adjusted EPS, $0.15 from business mix and $0.10 from FX. We’re actively offsetting all of this headwind about $0.20 through cost management and $0.05 through actions below-the-line, so no net change overall.
The PPI business system is enabling us to navigate the company very effectively through a dynamic macro-environment. As I mentioned, the 2023 guidance reflects a very strong financial outlook, and let me remind you of some of the key underlying assumptions that remain unchanged from the previous guidance. We continue to assume 7% core organic revenue growth from market growth of 4% to 6%. Within our core revenue, we expect $500 million of vaccines and therapies revenue in 2023, this is $1.2 billion less than the prior year, a 3% impact on core organic revenue growth. It’s worth noting that the majority of our vaccine and therapy revenue in 2023 is expected to be in our pharma services business. With regards to testing revenue, we continue to assume $400 million for 2023. We’re assuming the Binding Site acquisition will contribute approximately $250 million to our reported revenue growth this year.
Below-the-line, we expect net interest expense in 2023 to be approximately $480 million. We continue to assume that net capital expenditures will be approximately $2 billion in 2023 and free-cash flow is assumed to be $6.9 billion for the year. Our guidance includes $3 billion of share buybacks, which were already completed in January. We estimate the full-year average diluted share count will be approximately 388 million shares. And we’re assuming we’ll return approximately $540 million of capital to shareholders this year, through dividends, a 17% increase over 2022.
So turning now to the assumptions that have changed. As I mentioned earlier, our FX assumptions for the year has changed, we still expect FX to be a tailwind to revenue of approximately $100 million or 0.2%, where we now expect it to be a headwind to adjusted EPS of $0.06, but $0.10 more of a headwind than the previous guidance, due to changes in rates and the expected mix of our currencies. Guidance assumes adjusted operating margins for 2023 to be in the range of 23.8% to 23.9% for the year and the adjusted tax rate assumption has improved slightly from our initial guide, we now expect it to be 10.8% for the full-year.
And finally I wanted to touch on quarterly phasing for the year. Compared to our initial phasing assumptions we now expect a slightly higher weighting of revenue and adjusted EPS in the second-half of the year. We’re currently assuming that the first-half of the year represents approximately 48% of our full-year revenue dollars and 44% of our full-year adjusted EPS dollars. Q2 core organic growth is expected to be mid single-digits, probably best to model at a slightly lower than Q1.
To conclude, we delivered a very strong start to the year and we’re in great position to deliver differentiated performance for all our stakeholders in 2023. With that, I’ll turn the call-back over to Raf.
Rafael Tejada — Vice President Investor Relations
Thank you Stephen. Operator, we’re ready for the Q&A portion of the call.
Questions and Answers:
Operator
Thank you. [Operator Instructions] Our first question comes from Jack Meehan of Nephron Research. Jack, your line is open. Please go-ahead.
Jack Meehan — Nephron Research — Analyst
Thank you good morning. So my question is focused on Lab Products, biopharma services. First is on PPD so we’ve been getting some mixed signals so far this earnings around biotech customer demand. Marc, would love to get your perspective how did PPD grow this quarter, what does the outlook assume, has that changed at all? And then can you talk about award trends that you’re seeing? Thanks.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Jack, thanks for the question, good morning. Our clinical research business PPD, had a very strong start to the year. The growth continues to be in the mid-teens and it’s doing really well. We had strong backlog, we had good level of authorization, so that business is continuing to benefit from the revenue synergies, you’re seeing that start to come into the numbers this year and I’m very excited about the prospects, the team’s done a really good job of executing. Environment is definitely a little bit more challenging, but the team is doing a good job to go out and capture the business.
Jack Meehan — Nephron Research — Analyst
Great. Okay, and then one more on that segment is just would love to hear color around how the research channel performed this quarter. Can you just talk about core market demand and any share dynamics that you’re seeing? Thank you.
Marc N. Casper — Chairman, President and Chief Executive Officer
Our channel business, Fisher Scientific channel has done really well actually, consistently for quite a number of years. It plays an amazing role in enabling our customers to do the research that they’re doing and make sure they do that in an effective and efficient way. And the business is off to a good start, it’s had
Good growth and our best sense on share dynamics as it continues to win customers. So it’s a well-performing business.
Jack Meehan — Nephron Research — Analyst
Super. Thank you.
Marc N. Casper — Chairman, President and Chief Executive Officer
Thanks, Jack.
Operator
Thank you. Our next question comes from Rachel Vatnsdal of JPMorgan. Rachel, you line is open. Please go-ahead.
Rachel Vatnsdal — JPMorgan — Analyst
Perfect. Good morning, thanks for taking the question. So first off, two of your peers have recently talked about visibility within bioprocessing being pressured to more like three to six months of visibility versus historical of 9 to 12 months. So, can you just walk us through what’s your current level of visibility and is that different between customer set within large pharma versus some of these emerging biotech customers? And then also how did PPD and having that business impact your level of visibility there?
Marc N. Casper — Chairman, President and Chief Executive Officer
Sure. So Rachel good morning, thanks for the question. Maybe I’ll step-up a level first and then I’ll talk about the specifics of the question, because as I look and read some of the other industry participants reports so far, clearly a noisy quarter in the industry. And when I frame that as a reminder, when we started the year, we set our ambitious goals for 2023 right and we do that every year. For us, 7% core growth from an organic perspective against a 14% comparison and also have very strong earnings. So that’s sort of, as we came into the year. So what’s different in late April versus February 1 when we set out our guidance? Well, the first thing is we delivered a great start to the year, all right, great Q1.
Second, the macroeconomic environment is more challenging right and that leads to a slightly more cautious spend in all sectors of the economy, nothing to do with life science tools and pharma services but we also see that in some of our customers as well, in terms of the caution. Within our own company, a couple of our businesses are performing slightly better than our original guidance and that’s our Analytical Instruments business which had an excellent Q1 and we now have more visibility into Q3 for that business and that looks encouraging. The second business that’s doing a little bit better than our original guidance was specialty diagnostics is off to a strong start.
Bioproduction, which is where your question is really focused, we’re going to see in the first half more headwinds than our original expectation. It’s driven really by the customers are benefiting from the improved lead times that we’re delivering against because we brought our — completed our network expansion right. So customers can get products more quickly and our view is, this is a temporal phenomenon and we feel-good about the long-term prospects here. In terms of the specifics on — in terms of visibility and by customer sets and those things — I think the way that I think about it is long-term it’s an incredible market with great growth, it’s grown very high for many years in the past and has incredible tailwinds. It has reasonably good visibility because it’s related to customer production and our expectation is that the second-half of the year is better than the first-half of the year in terms of the view. As a reminder Rachel, it represents 10% of our revenues, so I think it’s important to keep that in the context as well.
Rachel Vatnsdal — JPMorgan — Analyst
Great, thank you. And then, maybe just one on instruments, analytical instruments grew 17% during the corner, you flagged that that’s one of the areas that’s been better-than-expected so far versus your initial guidance for the year. So, can you walk us through what are your latest expectations for analytical instrument growth for the year? And then are there any end-markets within AI that are just growing faster-than-expected? Thanks.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so in terms of our instruments business, we really are benefiting from very strong adoption of our innovation right. We just continue to bring out great products. As a reminder, during the pandemic we continue to fuel and accelerate our R&D pipeline and you’re seeing the benefit of it. We are capitalizing on the semiconductor — desire to move to the next-generation of nodes which uses our electron microscopy, we’re a key enabler for battery technology with our microscopes and our chromatography, mass-spectrometry business doing incredibly well.
So the strength here is broad-based. Obviously, the 17% growth in the quarter, very strong, we would expect a good level of growth in Q2 and what we had said at the beginning of the year so that would moderate in the second-half and we think that moderation will be less than we originally expected in Q3. So we expect it to be a solid Q3 and we’ll obviously have more visibility to Q4 when we report in July. So, we’re assuming that — better than we expected and in Q4 as we expected at this point, because that’s what we have visibility to. Thanks, Rachel.
Operator
Thank you. Our next question comes from Derik de Bruin of Bank of America. Derik, your line is open, please proceed.
Derik de Bruin — Bank of America — Analyst
Hi, good morning. Hey, so I’m curious, you’ve talked about ambitious guide and the markets being a little bit tougher yet you’re maintaining guidance because you’re offsetting some things right now. I guess, is there additional wiggle room to do further offsets if the market deteriorates further? Basically, it’s a question about your confidence in that guide and how much sort of like leeway is built into it? Thanks.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Derik, the way that we manage the company right, is the first thing we want to deliver differentiated performance in a given year that we would be proud of delivering and strengthen the company for the long-term, right, and that’s the first set of principles and that set of principles have served us very well for many years and when you look at our track-record we do a good job of delivering short-term and strengthen the long-term. When I think about the outlook for the year and where we are, we feel-good about the full-year guidance at this point in time-based on how Q1 has played out and the changes and we’ve laid out some of the assumptions around that for the balance of the year and if those assumptions are largely the way the year plays out, we’re going to be in great position. If those assumptions are too conservative we will beat these numbers. If those assumptions are too aggressive, then we will appropriately adjust guidance over time, right and I’m not shy about any of those dynamics, we try to give you total transparency and I feel good about our outlook based on-Q1 and the assumptions that we’re making.
Derik de Bruin — Bank of America — Analyst
Got it. And then going back — I mean, because we’re obviously getting a lot of questions on the whole bioprocessing and inventory issues. I know your businesses is more upstream focused than downstream and it looks like you’re maintaining the expectations you have for the COVID vaccine element, but can you just talk a little bit more about some of the dynamics in that space and why your business is a little bit different than some of the other ones and also just you talked about some moderating in bioproduction, just a little bit more clarity on that. Thanks.
Stephen Williamson — Senior Vice President and Chief Financial Officer
Just to kind of level-set for a second on the actual revenue for 2023, the $500 million of vaccines and therapies that’s pretty much all in our pharma services business, it’s not in bioproduction business.
Derik de Bruin — Bank of America — Analyst
Got it, okay.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so when I think about the dynamics here. On the COVID vaccines, as Stephen said my take is, it’s played out almost exactly as — Q1 is exactly where we anticipated when we look at our visibility to the $500 million, I feel very good about that in terms of it because we know the contracts that we have and what activity has been booked there, so that’s pretty straightforward. When I think about the bioproduction more generally, what I would say is in a very practical dynamics — if you go back to the pandemic, right huge demand right for these products and those companies that were successful and unsuccessful in trying to bring out therapies and vaccines for response to the pandemic.
That stressed lead times for everybody, obviously it varies definitely, by how much capacity, how well companies are owned, it’s different dynamics, but lead times got super extended right, for us it’s the nature of our products, our leadership in-cell culture media and single-use customers don’t really order extra. It’s not one of these things where you want to be stockpiling this stuff, because they’re very specific to the campaigns that you’re running, right. So, the dynamic becomes very simple, if we have a 30 week lead-time, which was extended during the pandemic, new order, 30 weeks with 30 weeks visibility. When we bring that lead-time back into normal to say 15 weeks for simplicity customers will work-through what they order because they don’t have to order as quickly, because they know we’re going to give them the product, right.
And one of the themes that we said throughout the pandemic was we work super closely with our customers like incredible on the dialog, so they trust that we’re going to deliver when we say. So, they didn’t over order in the time when lead times got extended and they’re ordering appropriately now, so can you call that to the month? No. Of course not.
But we have a reasonable view that the first-half is going to be a little bit softer than we originally had putting our expectations that the second-half starts to pick up and the good news is between instruments and specialty diagnostics that’s offsetting it that at this point so hopefully that’s helpful.
Derik de Bruin — Bank of America — Analyst
Great, thanks.
Marc N. Casper — Chairman, President and Chief Executive Officer
You’re welcome.
Operator
Our next question comes from Dan Brennan of Cowen. Dan, your line is open. Please go-ahead.
Dan Brennan — Cowen — Analyst
Great, thank you. Thanks for the questions. Marc, while we had to wait for the conference call to get the core organic guide, reiteration for Thermo, The Jets won up to you by giving us Aaron Rodgers trade before the draft, fans have to be excited for the year, I hope you are. So maybe just on bioproduction, a question there would you be willing to share with us just some color within the context of your biopharma outlook for 2023. How you’re thinking about the growth rates for your consumables business, the CDMO and PPD. I know in the last call you gave us PPD, but just trying to get a break-down or a sense of the different components for your biopharma outlook for the year.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Dan, thanks for the question and the spring — always spring is eternal in football because snap hasn’t been made yet, but effectively from my perspective, pharma and biotech it’s a good question. If you take — let’s focus on the market itself, right, when I think about the quarter we delivered mid-single-digit growth right. And when you think about what’s embedded in that, is obviously that’s where the vaccine and therapy roll-off is, from the prior year. So we did exactly as we expected so that basically had double-digit growth — I’m not a big normalization guy, but just to try to make it simple, if you didn’t have a vaccine and therapy roll-off, you’d have double-digit growth in that segment. So, most of the change from trajectory is around that.
I think the second thing to remember is that last year we grew 14%, this year we’re expecting to grow 7%. The expectation, obviously is therefore our growth while outstanding is going to be more moderate than last year and given that pharma and biotech is our largest customer segment, obviously our expectation is that growth will moderate. I would say largely Q1 was pretty similar to what we thought it would be with bioproduction being a little bit softer. You can say there’s a little bit more caution in the smaller biotech customers, but do I think it’s like dramatically different? I don’t, right and so we’re working through that and we have strength in other parts of our mix and that’s kind of where we are.
On all of the details of each of the businesses by customer set, we don’t really manage that way and on the bioproduction side, as I said a little bit earlier, in total, it represents about 10% of our revenue.
Dan Brennan — Cowen — Analyst
Great, thank you for that Marc. And then, maybe as a follow-up on an earlier question on instruments, you talked about better visibility so what is — you talked a lot about share gains as well, so maybe could you give us a sense of how you’re somewhat bucking the trend that the other peers are seeing after a strong, couple of years, you’re still seeing above corporate average growth, others are kind of citing more comps. So, what’s driving between FEIC [Phonetic], LCMS and any geographies or anything you want to share with us about the strength in your AI business for 2023?
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, the team’s doing a good job executing right. They’re doing a good job on navigating the various supply-chain things that happened over the last couple of years and our shipments are at a high-level and we’re going out and winning business. I think the strategy that the team has executed around breakthrough innovation — customers find money when the products are really relevant. I mean, that’s been my experience over long periods of time where if you have great products, customers want them. So that’s been a positive dynamic certainly for the Instruments business and what I would say is, we definitely have challenging comparisons this year. We’re off to a good start and I would expect that growth will moderate a bit in the second-half, but Q3 being a little bit better than we originally expected.
Dan Brennan — Cowen — Analyst
Great, thank you, Marc.
Marc N. Casper — Chairman, President and Chief Executive Officer
You’re welcome.
Operator
Thank you. Our next question comes from Matt Sykes of Goldman Sachs. Matt, your line is open, please proceed.
Matthew Sykes — Goldman Sachs — Analyst
Hi, good morning. Thanks taking my questions. Maybe Marc or Stephen, just first on sort of regional trends Stephen, you outlined some of the growth in the quarter for Europe and China, but just any incremental color on what you’re seeing, particularly in China across your business and how you think that those trends play-out over the course of this year?
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Ben, thanks for the question. China actually played out pretty much as we expected in the quarter right. So our expectation for Q1, was it was going to be slightly better than Q4 then we’d still see some of the impact of the unwind of the Zero COVID policy and that as the year progresses, it will continue to strengthen from there. When I look at the first-quarter in China, the business was down slightly the core growth actually was high-single-digits in the quarter, so that felt good. What I would say is, we expected stimulus to happen in the first-quarter, it did happen in the first-quarter so that played out — it was good to see the Chinese government release money to the academic institutions — you see that in our instrument business and so that played out well.
And so, I feel good about the outlook. Obviously, the geopolitical tensions are real and that’s an environment that it’s going to be around I would suspect for a while and we’ll navigate through, but China should be a good market for us this year and has been historically. Stephen, anything on the?
Stephen Williamson — Senior Vice President and Chief Financial Officer
Yes, on the other end-markets, I think there’s a lot of noise from the pandemic unwind, but when I kind of see through that, good growth really across all of main geographies, so nothing really to call out there.
Matthew Sykes — Goldman Sachs — Analyst
Got it, and then just maybe one high-level on PPD you talked about the growth there and obviously it’s been outgrowing peers, can we attribute any of that outsized growth to sort of the value proposition that being a part of Thermo might represent for your customer base or is it still too early to kind of see that potential growth impact come in, this is just PPD executing as it has been?
Marc N. Casper — Chairman, President and Chief Executive Officer
I think our team is doing a great job of executing right, they are out there serving customers and patients, so that customer is making a great choice to work with us, they’re doing a really good job. We clearly have a high-level of new authorizations, because of the combination of what Thermo Fisher brings and what PPD brought together, right. So, there’s a lot of customer interest — it shows up in authorizations, it’s showing up in our revenue now, that continues to build and I’m excited, next year will be year three and as a reminder that’s $250 million of revenue that we’re assuming from a revenue synergy next year. So, it’s really exciting in terms of where it is and I feel-good about the performance of the business and the outlook.
Matthew Sykes — Goldman Sachs — Analyst
Thank you.
Marc N. Casper — Chairman, President and Chief Executive Officer
Thanks Matt.
Operator
Thank you. Our next question comes from Vijay Kumar of Evercore. Vijay, your line is open. Please go ahead.
Vijay Kumar — Evercore — Analyst
Hey guys, thanks for taking my question and congrats on the steady trend [Phonetic] here. Marc, my first question for you, high-level I think your prior guidance for biopharma end-market was slightly north of corporate above 7% or thereabouts. Did that change at all Marc, and if it had changed where is the change coming from between CDMO, CRO and bioprocessing and could you just remind us what is Thermo’s exposure to early-stage biotech emerging biopharma?
Marc N. Casper — Chairman, President and Chief Executive Officer
Yes, so Vijay we gave like 80,000 foot directional views on the markets at the beginning of the year, to set the guidance context and when I think about the additional color that Stephen and I have provided today, it really says that it’s more business focused which is actually how we manage our company, Instruments Specialty, Diagnostics is a little bit stronger, bioproduction, a little bit softer primarily in the first-half, so that translates probably into tiny little changes within the end-markets, but nothing that really jumps out as something meaningfully different. What I would say is, in terms of the early biotech, those are a great customer set that we have done a fantastic job serving. Yesterday I was actually talking to roughly 400 members of that community at a customer event here in the Greater Boston area and the room was buzzing, not because I was speaking but rather just let me walking in and there is such energy and excitement. So why is that?
Because they’re bringing through cures that are going to make such an enormous difference to science is phenomenal, so there is clearly going to be more caution in that segment depending on the funding environment, but the science is great, the passion is extraordinary and we are company that people come to, to advance a molecule from a scientific idea to an approved medicine. So, it’s customer set we love, we’re going to do well and we obviously generate the vast majority of our revenue from a large pharma and biotech customers and they’re doing well and we’ve got a strong position there. So, hopefully that at least gives you the qualitative context of how to think about it.
Vijay Kumar — Evercore — Analyst
That’s helpful perspective Marc, and Stephen one quick follow-up for you. Second-quarter guidance, mid single I think you said second quarter perhaps below Q1, do comps still get easier for you in 2Q, so maybe just walk us through on that 2Q thought process.
Stephen Williamson — Senior Vice President and Chief Financial Officer
The main piece is just the timing on the bioproduction and instrumentation being stronger in Q3, as Marc outlined in terms of the potential guidance assumptions.
Vijay Kumar — Evercore — Analyst
Fantastic. Thanks guys.
Marc N. Casper — Chairman, President and Chief Executive Officer
Thanks Vijay.
Operator
Our next question comes from Dan Arias of Stifel. Dan, your line is open. Please go-ahead.
Dan Arias — Stifel — Analyst
Good morning, guys, thanks for the questions. Marc, on the services side, I’m just curious how the Unity business is performing in light of this sort of sustained period of instrument demand that we’re seeing here? Is acceleration something that we can expect there or is this more of sort of a steady-state growth rate at this point?
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Dan, thanks for the question. When I think about our Instrument and Equipment services business, what that business is as a reminder for investors is we service our fleets of instruments. We also work at pharmaceutical and biotech campuses, work for our customers to manage their inventory, do those activities, help them with some of the things that they need done to run their labs as well as service other people’s equipment and instrumentation. So that’s what we do. In general that is a steady, nicely growing business, because we’ve had very significant growth in the volume of our instruments over the last couple of years that becomes a trailing tailwind for the business because you have a year or so of warranty, so you don’t get any additional revenue, effectively, but as the warranty rolls off that does actually drive incremental demand, so your hypothesis there is correct. But that’s one that continues to strengthen at this part of the cycle.
Stephen Williamson — Senior Vice President and Chief Financial Officer
Yeah, and then Dan particularly on the on electron microscopy business where customers can’t service themselves so you have some customers that can be efficient at service — kind of lower-end instrumentation, but from electron microscopy standpoint, they’re really looking for us to step up and help them with that so that continued — as Marc said, that continued tailwind is very significant.
Dan Arias — Stifel — Analyst
Yeah okay, helpful. And then Stephen while I have you, just on the variables of the equation that have changed slightly underneath and unchanged guide overall, is there anything in terms of the evolving expectations for the business units themselves? Marc made mention of some things — some businesses that are doing better than others. So, just sort of wanted to sum that up when we think about segment trajectory and just modeling those going-forward? Thanks.
Stephen Williamson — Senior Vice President and Chief Financial Officer
Yeah. I think, we outlined the key changes. I think one thing that’s hard for people to model is to kind of where the vaccines and therapies changes when I think about Q1 that was all in the Life Science Solutions segment — the Biosciences business, as well as bioproduction. So, from a year-over-year change that was I think about an 8 percentage point impact on segment, that lessens as a headwind when I think about that going-forward. But still, most of that change in that revenue stream is in that segment as I think about the year as a whole. But nothing significant changing underneath other than we’ve already identified in terms of the overall guide.
Rafael Tejada — Vice President Investor Relations
Operator, we have time for one more question, please.
Operator
Of course, our final question of today comes from Puneet Souda of SVB Securities. Puneet, your line is open. Please go-ahead.
Puneet Souda — SVB — Analyst
Yeah hi, Marc, good morning and congrats here. Just I’ll stick to one and maybe 1.5 question. Capital deployment, 2022 you did two deals, PeproTech earlier in there and then Binding Site, wondering how the outlook is looking for capital deployment this year, maybe talk a little bit about your expectations for what you’re seeing from market participants in both public and private markets? And then, just briefly on the Inflation Reduction Act. Could you outline what you’re hearing from your larger pharma customers and wondering if they’re changing how they’re allocating their R&D going-forward? Thank you.
Marc N. Casper — Chairman, President and Chief Executive Officer
Yeah, so Puneet thanks for the questions. In terms of the IRA, I think customers are working through that, in terms of what the implications and does that adjust of any of their long-term decision-making about what our preferred and what’s their clinical trial strategy. We haven’t seen anything material change at this point. I know there’s certainly a lot of dialog with government on trying to make sure those policies do what they were intended to do.
From a capital deployment perspective, this is a good environment from my perspective, because you have less competition because of higher interest rates from certainly private-equity and so forth, so I think there’s always competition but I think that’s good because that helps you pick and choose and get things at an appropriate valuation, so I think we will continue to be active.
Our pipeline is super busy like, I’m very excited about what we’re looking at — you never know how these things actually play out in reality, but there’s plenty going on and we’ll be aggressive if the right transaction is available to us, so that’s the benefit of the company performing well and a great track-record of creating value through capital deployment. So thanks for the questions. I think at this point, I’ll do a quick wrap-up.
So thanks everyone for joining us on the call today. We’re very pleased to deliver a strong quarter. We’re incredibly well positioned to continue to deliver differentiated performance as we continue to create value for all of our stakeholders and build an even brighter future for our company. I’m looking-forward to updating you on our upcoming Investor Day on May 24, see you in New York City or virtually. And as always, thank you for your support of Thermo Fisher Scientific.
Operator
[Operator Closing Remarks]